Trial Profile

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PDC 1421 (Primary)
Indications Attention-deficit hyperactivity disorder
Focus Therapeutic Use
Sponsors BioLite Inc

Most Recent Events

14 Nov 2024 According to a ABVC Biopharma media release, the Company is preparing for an FDA End-of-Phase 2 meeting to finalize the Phase III protocol.
19 Jan 2023 Results published in the ABVC Biopharma Media Release.
19 Jan 2023 According to a ABVC Biopharma media release, results from this trial were presented at the 2023 Conference of The American Professional Society of ADHD and Related Disorders (APSARD) Poster Session.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com